Pegfilgrastim for primary prophylaxis of febrile neutropenia in breast cancer patients undergoing TAC chemotherapy.

Jihyoun LeeJong Eun LeeZisun KimSun Wook HanSung Mo HurSung Yong KimMin Hyuk LeeCheol Wan Lim

Published in: Annals of surgical treatment and research (2018)

Incidence of FN was low during the chemotherapy by primary prophylaxis with pegfilgrastim. The ANC nadir was seen on day 7 after chemotherapy. Bone pain with pegfilgrastim was well tolerated during TAC chemotherapy.

Keyphrases

chemotherapy induced
locally advanced
patients undergoing
chronic pain
risk factors
neuropathic pain
bone mineral density
young adults
spinal cord injury
urinary tract infection